Heart failure & cardiomyopathies
The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry
Main finding · MortalityResult — go to the resultHazard ratio 1.53 95% CI 0.77–3.02Authors' conclusion
AHF patients with tolvaptan use had more congestive status with poorer in-hospital outcomes and higher short-term mortality than those without tolvaptan use.
Study context
- Population
- Patients with acute HF in the Kyoto Congestive Heart Failure registry, excluding dialysis and prior or unknown tolvaptan useof 4056 consecutive patients
- Participants
- 3,802 patients
- Exposure
- Tolvaptan use vs no tolvaptan use
- Tolvaptan usen = 773
- No tolvaptan usen = 3,029reference
- Outcome
- All-cause mortality
- Follow-up
- 90 days after admission
Methodological detailsmulticentre, consecutive patients
- Multicentre
- Consecutive patients
Main finding
Mortality
Hazard ratio
1.53
95% CI 0.77–3.02
P = 0.22
By group
Tolvaptan usevs No tolvaptan use
HR 1.53 (95% CI 0.77–3.02); P = 0.22
As reported in the abstract
Observational data: associations, not effects.
Further findings
Hospital stay
- Hospital stay: P < 0.0001
Tolvaptan use prevalence across centres
- Prevalence of tolvaptan use across centres
- 48.7% to 0%
Factors independently associated with tolvaptan use
- DM, poor medical adherence, oedema, pleural effusion, hyponatraemia, eGFR < 30 mL/min/1.73 m², moderate/severe tricuspid regurgitation, dobutamine within 24 h, additional inotropes beyond 24 h
Safety
Worsening renal failure
Worsening HF
- Worsening renal failure: P < 0.0001
- Worsening HF: P < 0.0001
Original publication
The Characteristics and Outcomes in Patients with Acute Heart Failure Who Used Tolvaptan: From KCHF Registry. ESC Heart Fail. Published 29 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →